SynthesisFrontiers in oncology2026
Genomic landscape and subgroup stratification of thymic epithelial tumors: a systematic meta-analysis of next-generation sequencing data.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Thymic epithelial tumors are rare cancers of the anterior mediastinum with heterogeneous clinical behaviors. Despite numerous attempts to characterize their mutational landscape, a comprehensive understanding of their genetic alterations remains limited due to small sample sizes. Methods: To address this gap, we conducted a systematic meta-analysis of somatic mutations reported in 729 patients across twenty studies, integrating single-variant data into a unified dataset. Results: This approach identified three molecular subgroups with distinct biological and clinical features. Tumors harboring GTF2I mutations were typically indolent, exhibited low mutational burden, and showed enrichment in pathways related to cell adhesion. Tumors with TP53 mutations displayed high mutational load, activation of receptor tyrosine kinase and mitogenic signaling, and corresponded to aggressive clinical behavior. Tumors lacking both GTF2I and TP53 mutations revealed intermediate pro les, characterized by alterations in epigenetic regulation and extracellular matrix organization. Mutational signature analysis indicated that age-related processes predominate in less aggressive tumors, while DNA repair de ciency characterizes those with TP53 mutations. Network and pathway analyses revealed convergent oncogenic hubs and distinct signaling dependencies across subgroups. Discussion: This large-scale integrative study provides a re ned map of the genetic landscape of thymic epithelial tumors, highlights biologically meaningful heterogeneity, and establishes a framework to guide future research and the development of targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.